Shares shifted as Senti Biosciences (SNTI) jumped 7.9% to $0.37 after authorizing a $2 million third tranche of senior secured convertible notes — a fresh cash injection for a company that has openly warned it may not survive past the fourth quarter of 2026. The move buys time, but the price of that time is steep for existing shareholders.
A Tiny Lifeline for a Company Running on Fumes
Senti disclosed that substantial doubt exists about its ability to continue as a going concern, with just $6.5 million in cash as of June 30, 2026.
In August, it issued $4 million in additional convertible notes, but even with those proceeds, management warned it may not be able to maintain operations starting as early as Q4 2026. The new $2 million tranche adds weeks, not quarters, to the runway given that the company burned $7.5 million in operating cash in Q1 alone.
The Dilution Math Is Brutal
The roughly 15.97 million shares registered for resale from the first tranche alone represent about 51.3% of outstanding stock, and the company itself has warned that note exchanges "could be significantly dilutive and may cause a decline in its share price."
The notes carry no interest unless the company defaults, but feature a 200% cash payback if not converted — meaning Senti would owe double the principal in cash at maturity — plus full-ratchet anti-dilution protection that resets the conversion price downward every time the stock falls.
Nasdaq Is Watching — And Not Happily
On August 27, Nasdaq notified Senti it had breached both the $1.00 minimum bid price rule and the $2.5 million minimum stockholders' equity requirement, citing a stockholders' deficit of $3.4 million.
The company has until February 23, 2027 to regain bid-price compliance. At $0.37, the stock needs to nearly triple just to stay listed.
The Bet Is Entirely on One Drug
Senti's sole clinical-stage asset is an off-the-shelf cell therapy designed to target blood cancers like acute myeloid leukemia.
With an accumulated deficit of $375.5 million and collaboration revenue of just $33,000 in the first half of 2026 , there is no commercial revenue to cushion any setback. Investors bidding up the stock on a $2 million note are betting that drip-fed financing from the company's largest shareholder, Celadon Partners, can keep the lights on long enough for clinical data to matter.